Monomorphic MHC class II determinants are attractive targets for immunomodulation. HLA-DR ligation on antigen-presenting cells (APCs) can dramatically alter their function or induce cell death. In monocytes, HLA-DR triggering diminishes their capacity to stimulate T cell proliferation. To further investigate this monocyte-dependent T cell inhibition, we activated human T cells 6 HLA-DR triggering on APCs and tested whether this can induce T cell anergy. Only anti-HLA-DR, but not antiproliferative control agent anti-CD45, could modulate monocytes in primary cultures with stimulated T cells, so that T cells were hyporesponsive during re-stimulation. Cell separation studies demonstrated that HLA-DR ligation on monocytes is sufficient for mediating T cell anergy. Secretion of monokines was severely reduced after primary culture. Monocytes anergized independently of soluble factors. Extracellular signal-regulated kinase (ERK) phosphorylation occurred early with anti-HLA-DR, but late with anti-CD45 antibody. However, ERK inhibition did not reverse the T cellanergizing potential of HLA-DR-ligated monocytes implicating other signaling pathways involved in tolerance induction. When analyzing the anergized T cells, they were refractory to exogenous IL-2 and characterized by defective secretion of various cytokines. Expression of CD25, CD28, intracellular CD3z and CTLA-4 was reduced. The hyporesponsive T cells up-regulated cell-cycle inhibitors p27 kip1 and p21 cip1 in correlation with human T cell anergy. In contrast, caspase-3 and -8, known to contribute to T cell proliferation, were equally decreased in anti-HLA-DR-and anti-CD45-inhibited cultures. In summary, anti-HLA-DR treatment can generate tolerogenic monocytes transmitting T cell anergy that may be exploited for future immunomodulatory strategies to treat immune-mediated disease states.
Introduction
T cell tolerance is maintained by a combination of central and peripheral mechanisms (1, 2) . Since intrathymic deletion of self-reactive T cells is incomplete (3), several T cell-intrinsic and -extrinsic mechanisms exist to ensure peripheral tolerance (2) . While tolerogenic antigen-presenting cells (APCs) and suppressor T cells actively tune down self-reactive T cells, they can also be directly regulated by deletion, anergy, phenotype skewing and ignorance (2) . T cell anergy is a long-lasting state of functional unresponsiveness characterized by impaired proliferation, cytokine secretion or effector function (4) (5) (6) (7) (8) . Recently, the existence of anergic suppressor T cells has been re-appreciated (9) , but the precise role of anergizing, instead of deleting potentially autoreactive T cells is not well understood. There are various mechanisms leading to anergy on the cellular and molecular level [for review see (4) (5) (6) (7) ]. Proteolytic processes (involving caspases for instance, among other enzymes) have been associated with this phenomenon (10) , but caspases (usually executing cell death) also coordinate T cell proliferation paradoxically (11) (12) (13) (14) (15) (16) . Recently, the ubiquitination machinery has been shown to be involved in murine T cell anergy (7) , but it remains to be shown that the associated E3 ubiquitin ligases are also active in standard models of human T cell anergy. On the other hand, inhibitors of cell-cycle progression have been repeatedly linked to human and murine T cell anergy (6, (17) (18) (19) (20) (21) (22) (23) (24) , although some controversy still exists (25, 26) . Taken together, there is still considerable inconsistency between the various models of human and murine T cell anergy and new model systems should be helpful to further understand this complex process.
Another attractive, but indirect way to silence T cells is to tolerize APCs that subsequently suppress T cell function (27) (28) (29) (30) . This mode of tolerance induction should be preferable as it not only silences pathogenic T cells but also APCs that could otherwise potentially reverse the inhibitory process (31) . In principle, APC-mediated inhibition of T cells can either be short lived or lead to long-lasting T cell anergy (32) . Generating APCs that mediate T cell anergy would be more desirable than brief T cell inhibition as it could possibly create a tolerogenic state (2) . Therefore, it would be useful to identify targets that induce anergizing APCs. In addition, identifying new forms of tolerance induction might help to understand the diverse mechanisms of peripheral tolerance (2) .
Besides their well-known function as antigen-presenting molecules (33) and regulators of naive lymphocyte homeostasis (34, 35) , MHC molecules are capable of transmitting signals (36) (37) (38) . T cell and APC interactions have been demonstrated to trigger MHC class II signaling (39) . MHC class II ligation can alter survival (40) (41) (42) (43) (44) (45) or function (46) (47) (48) (49) depending on cell type and experimental setting. It has been shown that monocyte-dependent T cell proliferation is inhibited by anti-MHC class II mAb without induction of apoptosis (47) (48) (49) . Any anti-proliferative but not apoptosis-inducing agent is potentially creating anergy, if the anti-proliferative state can be sustained. In search for novel tolerance-inducing mechanisms, we tested if anti-HLA-DR treatment of human PBMC is capable of inducing T cell anergy.
In this paper, we show that anti-HLA-DR, but not another anti-proliferative control agent (anti-CD45), induces T cell anergy transferred via monocytes in a manner that is independent of soluble factors. The HLA-DR-triggered monocytes do not resemble 'alternatively activated macrophages' (AAMU) but display early extracellular signal-regulated kinase (ERK) phosphorylation when examining their signal transduction. Furthermore, they induce profound T cell hyporesponsiveness that is refractory to exogenous IL-2 and characterized by reduced production of various cytokines. The anergized T cells selectively up-regulate cell-cycle inhibitors p27 kip1 and p21 cip1 on the protein level, explaining potentially the hyporesponsiveness as both molecules have previously been linked to T cell anergy (6, (17) (18) (19) (20) (21) (22) (23) (24) .
Methods

Cell preparation and cell culture
Peripheral blood was drawn from normal healthy subjects who gave their consent to do so in accordance with the Institutional Review Board at each institution (University of Erlangen-Nuremberg and University Medical Center Schleswig-Holstein). PBMCs from normal healthy donors were isolated from peripheral blood by Ficoll-Hypaque (BAG, Lich, Germany) density gradient centrifugation, washed twice with PBS and re-suspended in RPMI 1640 (Gibco BRL, Eggenstein, Germany) supplemented with 4 mM L-glutamine, 10 mM HEPES buffer, 100 U ml À1 penicillin, 0.1 mg ml À1 streptomycin (all BioWhittaker, Verviers, Belgium) and 10% (v/v) heat-inactivated (Gibco BRL). For generation of lymphoblasts, freshly isolated PBMCs were activated with 1 lg ml À1 anti-CD3 (OKT-3) for 5-7 days (at 37°C in a humified atmosphere containing 5% CO 2 ). Lymphoblasts were extensively washed and re-stimulated as indicated in the text. In parallel to OKT-3 lymphoblast generation, PBMCs were cocultured with OKT-3 plus anti-HLA-DR mAb 9.3F10 or OKT-3 plus anti-CD45 mAb GAP8.3. GAP8.3 mAb served as a control agent as it is of the same isotype as 9.3F10 and could similarly inhibit OKT-3-mediated proliferation without induction of apoptosis [see also Fig. 1A and (50) ].
Antibodies and reagents
IL-2 (10 U ml À1 ) was from Roche (Mannheim, Germany). Hybridoma cells producing CD3 mAb OKT-3 (IgG2a, 1 lg ml À1 ), HLA-DRb chain mAb 9.3F10, HLA-DRa chain mAb L243 and pan-CD45 mAb GAP8.3 (all IgG2a, 10 lg ml À1 ) were purchased from the American Type Culture Collection (Rockville, MD, USA). Given that anti-HLA-DR mAb 9.3F10 and anti-CD45 mAb GAP8.3 share the same isotype (IgG2a), anti-CD45 also acts as an isotype control, in addition to having functionally similar effects on primary stimulation of PBMCs (see Fig. 1A ). The optimal dose for HLA-DRb chain mAb 9.3F10 was confirmed with dose-response experiments (Supplementary Figure 3 , available at International Immunology Online). Similar experiments were performed for determining the dose for HLA-DRa chain mAb L243 (data not shown). All four antibodies were purified from hybridoma cell supernatant using the FPLC unit LCC 500 plus (Pharmacia, Erlangen, Germany) employing HiTrap Protein A Sepharose columns also from Pharmacia. Anti-CD28 mAb 9.3 was a kind gift from Bristol Myers Squibb (Princeton, NJ, USA). PHA (1 lg ml
À1
) and phorbol myristate acetate (PMA) (10 ng ml À1 ) were purchased from Sigma (Deisenhofen, Germany) and ionomycin (1 lmol l
) from Calbiochem (Bad Soden, Germany).
For FACS analysis, different combinations of FITC-and PE-conjugated mAbs have been used. Conjugated antibodies directed against the following antigens were purchased from Immunotech (Marseille, France): CD3, CD4, CD8, CD45RA, CD45R0, CD14 and CD11b. CD28, CD25, CTLA-4 and CD95 mAbs were from BD PharMingen (San Diego, CA, USA). CD3f chain mAb was purchased from Santa Cruz Biotechnology (Heidelberg, Germany). Bcl-2 mAb was from DAKO (Glostrup, Denmark). All isotype controls (IgG1 and IgG2a) were also from Immunotech.
Antibodies against p21 cip1 and p27 kip1 were purchased from BD Biosciences; the antibody recognizing intact as well as cleaved caspase-3 were obtained from Cell Signaling (Frankfurt, Germany). ERK1/2 or phosphorylated ERK1/2 antibodies were purchased from Cell Signaling as well. The ERK inhibitor PD 98059 was obtained from Calbiochem (Darmstadt, Germany).
Quantification of early, late apoptosis and necrosis
Microscopic examination of the cell cultures prone to undergo apoptosis revealed morphological changes like zeiosis. Microscopic discrimination of cells not being capable of excluding trypan blue staining grossly indicated the total cell number of currently dying cells. Apoptotic cells were quantified by flow cytometry. Phosphatidylserine exposure on the outer leaflet of the plasma membrane was detected by staining with FITC-conjugated Annexin V (AxV; Roche) in propidium iodide (PI; Sigma) containing staining buffer for 0.5-1 h at 4°C in the dark. After flow cytometric analysis, four populations can be distinguished as previously described (51, 52) . The populations are depicted in Supplementary Figure 1 Proliferation assays and mixed lymphocyte reaction [ 3 H]-thymidine uptake and incorporation into genomic DNA to quantify cellular proliferation was measured as previously described (53) . Briefly, 1 3 10 5 PBMCs or lymphoblasts were incubated for 72 h in a total volume of 150 ll medium in a 96-well round-bottom (flat bottom if plastic-bound antibodies were used as stimulating agents) microtiter plate (Costar, Cambridge, MA, USA) with the indicated reagents in triplicates at 37°C and 5% CO 2 . Samples were pulsed for the last 6 h with 0.5 lCi per well [ ) per well were stimulated in triplicates with soluble OKT-3 alone or in combination with IL-2 along with medium, HLA-DR mAb 9.3F10 or pan-CD45 mAb GAP8.3. Proliferation was quantified as specified in Methods. Numbers are mean values 6 SEMs of five independent experiments. P values for OKT-3 stimulation are as follows: medium versus 9.3F10, P = 0.0006 (***) and medium versus GAP8.3, P = 0.0023 (**). P values for OKT-3 with IL-2 stimulation: medium versus 9.3F10, P = 0.0182 (*) and medium versus GAP8.3, P = 0.0373 (*). (B) PBMCs were activated for 5-7 days during primary culture with OKT-3 alone, OKT-3 plus 9.3F10 mAb or OKT-3 plus GAP8.3 mAb. Cells were thoroughly washed, and 1 3 10 5 cells per well were re-stimulated with the reagents as indicated (p.b. = plate bound). Proliferation was quantified as specified in Methods. Numbers are mean values 6 SEMs of nine independent experiments. Statistical significance was calculated for optimally re-stimulated cells with p.b. OKT-3 plus IL-2 or anti-CD28. P values for p.b. OKT-3 + IL-2 re-stimulation are as follows: OKT-3 pre-treated versus OKT-3/9.3F10 pre-treated, P = 0.0304 (*) and OKT-3 pre-treated versus OKT-3/GAP8.3 pre-treated, P = 0.215 (not significant, ns). P values for p.b. OKT-3 + anti-CD28 re-stimulation: OKT-3 pre-treated versus OKT-3/9.3F10 pre-treated, P = 0.0016 (**) and OKT-3 pre-treated versus OKT-3/GAP8.3 pre-treated, P = 0.1702 (ns). (C) PBMCs were activated for 5-7 days during primary culture with OKT-3 alone or OKT-3 plus 9.3F10 mAb. Cells were thoroughly washed, and 1 3 10 5 cells per well were re-stimulated with irradiated allogeneic PBMCs as follows. Cells from the same donor were set up at day zero and re-cultured for 3, 5 or 7 days, respectively. Proliferation was quantified as described above, at days 3, 5 and 7 during secondary cultures representing a continuum for each starting population of donor cells examined. One out of three representatives experiments is shown given the donor-dependent variation in MLR-induced proliferative responses.
by liquid scintillation detected by a b counter from Pharmacia (Freiburg, Germany).
For plate binding of anti-CD3 mAbs, 96-well flat-bottom plates were coated with 50 ll OKT-3 at 1 lg ml À1 in 50 mM Tris-HCl (pH 9.5) and incubated for 1-2 h at 37°C or for 1-2 days at 4°C for optimal plate binding. Prior to usage, plates were washed two to three times with 200 ll Hanks solution (University Pharmacy and University of Erlangen-Nuremberg) per well.
Mixed lymphocyte reactions (MLRs) were performed using irradiated allogeneic PBMCs (3000 Gy) at a 1:1 ratio. Proliferation was measured as described above, but at three different time points (days 3, 5 and 7 during secondary cultures). Importantly, equal cell numbers from the same donor were split into three flasks that were set up at the same time point under identical culture conditions but harvested after 3, 5 or 7 days, respectively. This set-up allowed comparison of proliferative responses at day 3, 5 and 7, representing a continuum in time for each set of donor cells examined.
Flow cytometric analyses
Analysis of morphological changes seen in the forward scatter (FSC) and sideward scatter (SSC), surface and intracellular detection of various molecules and apoptosis quantification with AxV/PI as described above were performed using an EPICS XL TM flow cytometer (Coulter, Hialeah, FL, USA). Surface staining with different combinations of FITC-and PEconjugated mAbs and their appropriate isotype controls was achieved by incubation of 1 3 10 5 cells with the mAb cocktails for 15-30 min at 4°C in the dark. After washing the cells with PBS/1% BSA (Sigma), cells were analyzed by flow cytometry or alternatively fixed with 1% PFA (Sigma) until analysis.
Intracellular staining of CTLA-4, Bcl-2 or the CD3f chain was preceded by fixation and permeabilization. Cells (2 3 10 5 ) were fixed by incubation for 30 min with 1% PFA in PBS. After washing, cells were permeabilized by re-suspending them in 0.1% saponin (Sigma) in PBS plus 2% BSA for 10 min. Staining was performed as described for surface detection. Negative control antibodies yielded in <1% falsepositive cells in all experiments.
Measurement of cytokines in culture supernatants
Supernatants were collected at the end of the primary culture period and after 2 days of re-stimulation in 24-well plates. IL-2 and IL-10 in culture supernatants were measured using ELISA kits from R&D Systems (Wiesbaden, Germany). For measurement of IFNc and IL-4, capture anti-cytokine antibodies and biotin-linked detection antibodies (both from BD PharMingen) were used along with streptavidin-peroxidase and peroxidase substrate ABTS (Roche) following the manufacturer's recommendations. Tumor necrosis factor a (TNFa), IL-1b and IL-6 were measured with an automated immunoanalyzer (Immulite TM , DPC Biermann, Bad Nauheim, Germany) according to the manufacturer's instructions.
Cell separation studies
PBMCs were isolated as described above. CD3+ T cells were purified using a Pan T cell Isolation Kit TM from Miltenyi Biotec (Bergisch Gladbach, Germany) according to the manufacturer's protocol. A MidiMACS system was used and LS columns were applied. During the entire separation procedure, cells were kept on ice and in a degassed buffer containing 0.5% BSA and 2 mM EDTA. Purity was confirmed by FACS analysis (>90% CD3 positive) and by the lack of proliferation to PHA (1 lg ml À1 ) in a 3-day [
3 H]-thymidine incorporation assay (residual APCs would have triggered T cell proliferation in response to PHA).
Monocytes were isolated by plastic adherence. Freshly isolated PBMCs were incubated in 175-cm 2 culture flasks for 3 h at 37°C followed by extensive rinsing to remove the nonadherent cells. In order to better characterize adherent cells, control flasks were filled with ice-cold PBS for 5-10 min. followed by detachment of cells with a cell scraper. FACS analysis revealed a purity of CD14-positive and CD11b-positive cells >80%. For mixing experiments, adherent cells or T cells were incubated for 1.5 h with 9.3F10 or mock. After extensive washing, cells were mixed as stated below and OKT-3 was added for an additional incubation period of 5-7 days.
Determination of caspase activation
The activity of caspases in whole-cell lysates was determined in vitro using the fluorogenic substrates zDEVD.AFC for caspase-3 or zIETD.AFC for caspase-8 (both from Merck Biosciences, Darmstadt, Germany) as previously described (54) .
High-throughput immunoblotting
Cells from five different anergy experiments were lysed after 5-7 days of primary culture. One percent SDS and a protease inhibitor cocktail were added to the lysis buffer [150 mM NaCl, 50 mM Tris-HCl (pH 7.4), 1% NP-40, 1% Triton X-100, 0.25% Na-deoxycholate, 5 mM EDTA, 1 mM NaF and 1 mM Na 3 VO 4 ) prior usage. Only equivalent amounts of lysate from each experiment were pooled and analyzed by western blotting for various protein expression levels using a customized PowerBlot Miniarray (BD Biosciences) (55) . Blotting of each pooled lysate was repeated three times. Data analysis included raw and normalized signal intensity data from each blot (data not shown).
Western blotting
Western blotting of lymphocyte lysates with p21 cip1 , p27 kip1 and intact/cleaved caspase-3 antibodies was performed as previously described (15) . Western blotting of monocyte lysates was performed as follows: human monocytes were purified by counterflow centrifugation as previously described (15) . Monocytes were left unstimulated or stimulated for 15 min with TNF (50 ng ml
À1
) as positive control for ERK activation. In parallel, monocytes were treated with 10 lg ml À1 mAb 9.3F10 or GAP8.3. After various incubation times, cells were lysed using TNE buffer (15) and equal protein amounts were analyzed for total ERK1/2 or phosphorylated ERK1/2.
Statistical analysis
Student t-test was performed with InStat software (http:// www.graphpad.com) where appropriate and P values were stated in the figure legends. In addition, P values were depicted in the figures as symbols in the following order of statistical significance: not significant, if P > 0.05; significant (*), if P = 0.01-0.05; very significant (**), if P = 0.01-0.001 and extremely significant (***), if P < 0.001.
Results
HLA-DR and CD45 triggering both inhibit proliferation of human PBMC without induction of apoptosis, but only HLA-DR treatment of PBMC results in T cell anergy
In freshly isolated PBMC, both HLA-DR mAb 9.3F10 and pan-CD45 mAb GAP8.3 profoundly inhibited cellular proliferation in response to anti-CD3 mAb OKT-3 (Fig. 1A) . Both antibodies are of the same isotype (see also Methods). Inhibition was sustained >50% even when IL-2 was added (Fig.  1A) . Accessory cell-independent activation via PMA and ionomycin abolished the inhibitory capacity of either mAb [counts for PBMC without mAb: 11.049 counts per minute (c.p.m.); 9.3F10 added: 11.279 c.p.m. and GAP8. ). This was also true when combined with anti-CD28 or IL-2 indicating that, in general, inhibition of T cell proliferation is indirect. Apoptotic or necrotic cell death was not increased as determined by trypan blue exclusion and AxV/PI double staining (AxV/PI double-negative cells after 5-day OKT-3 culture were 65.8 6 2% without and 72.7 6 5% with 9.3F10; n = 3; see Supplementary Figure 1 , available at International Immunology Online). Morphologic characterization of the three cell populations (no anti-proliferative agent, anti-HLA-DR or anti-CD45) by light microscopic inspection and flow cytometry (i.e. FSC/SSC) revealed that only the proliferating cells acquired a blast-like phenotype, whereas anti-HLA-DR-or anti-CD45-inhibited lymphocytes remained naive; that is small and without significant shifts in FSC/SSC.
In order to test whether the anti-proliferative effect would induce an anergic state in T cells, we set up the following primary and secondary cultures similar to other in vitro models of T cell anergy [e.g. (56)]: cells were activated with OKT-3 for 5-7 days alone or in combination with anti-HLA-DR or anti-CD45. After extensive washing, lymphocytes were re-stimulated with plate-bound anti-CD3 alone or in combination with IL-2 or anti-CD28 leading to vigorous proliferation of regularly activated T cells from primary culture (Fig. 1B) . Pre-treatment with anti-HLA-DR, but not anti-CD45, however, left T cells hyporesponsive to these stimuli (Fig. 1B) including increased concentrations of plate-bound anti-CD3 (10 lg ml
À1
; data not shown). Hyporesponsiveness was not due to enhanced cell death upon re-stimulation as determined by AxV/PI double staining (data not shown). Furthermore, the anergic cells showed reduced and delayed proliferation during allogeneic MLRs compared with the vigorous response of control pre-treated cells with a peak proliferation at day 3 (Fig. 1C) .
To differentiate whether anergy was due to epitopespecific signaling via the HLA-DRb chain (recognized by mAb 9.3F10) or by the HLA-DR molecule in general, we also tested the anergy-inducing potential of the anti-HLA-DRa chain-binding mAb L243. This mAb also induced hyporesponsiveness to the above-stated stimuli (data not shown) indicating that general triggering of monomorphic determinants of HLA-DR can induce anergy.
Anti-HLA-DR-treated monocytes are mediating T cell anergy Since HLA-DR molecules are expressed by a variety of APCs and by activated human T cells (33, 57, 58) , we next wanted to investigate the specific cell type responsible for mediating T cell anergy. Therefore, we separated T cells and monocytes of the same donor by MACS or plastic adherence, respectively. Each sub-population was pre-incubated with anti-HLA-DR for 1.5 h under identical conditions. After extensive washing, the pre-treated cells were mixed with untreated cells of the other sub-population, i.e. anti-HLA-DRpre-treated monocytes with mock pre-treated T cells or anti-HLA-DR-pre-treated T cells with mock pre-treated monocytes. Both sub-populations with mock pre-treatment were also mixed together as a control. Next, the three different groups (monocyte, T cell and mock pre-treated) were all activated with OKT-3 for 5-7 days and re-stimulated as described above. Mock pre-treated cells proliferated well in response to re-stimulation, whereas HLA-DR triggering on monocytes transferred the anergic state to T cells ( Fig. 2A) . A minor inhibitory effect after T cell pre-treatment could be observed possibly due to residual antibodies bound to T cells (despite extensive washing) that detached later during the primary activation and targeted monocytes. Pre-treatment of adherent cells was clearly sufficient to induce profound anergy ( Fig. 2A) and anti-HLA-DR added during re-stimulation of (HLA-DR expressing) lymphoblasts did not influence their proliferation (Fig. 2B) . Taken together, this indicates that T cell anergy is indirectly mediated by altering monocyte function via HLA-DR, instead of direct modulation of HLA-DRexpressing T cells as shown for a T h 1 clone (59).
Anti-HLA-DR-tolerized monocytes are distinct from AAMU 'Alternative activation' of macrophages has been shown to induce a tolerogenic state [reviewed in (27, 28, 60) ]. These AAMU can mediate T cell anergy and are characterized by up-regulation of CD14, macrophage mannose receptor (CD206) and HLA-DR among others (27, 28, 60, 61) . We therefore investigated their phenotype and function after activation during primary culture. Secretion of the monokines TNFa, IL-1b and IL-6 was strongly inhibited (Fig. 2C ), but this was not specific to the anergy-inducing monocytes since anti-CD45 treatment also induced similar inhibition (Fig. 2C) . Furthermore, inhibition of monokine secretion was completely prevented by IL-2 (data not shown).
Flow cytometric analysis of 2-day-primed monocytes under conditions as described above did not indicate that AAMU were induced in our system; there were no significant changes in CD14 and CD86 expression between the three groups, while CD206 was not detectable and HLA-DRdetected with a FACS mAb recognizing a different epitope than 9.3F10 mAb-was slightly down-regulated (average mean fluorescence intensity of control, anti-HLA-DR-and anti-CD45-treated cells was 26.3 6 3 versus 19.7 6 3 versus 30.3 6 4, respectively, with no changes in % HLA-DR-positive cells). In addition, soluble factors were not involved in monocyte-induced T cell anergy since supernatants from 2-or 4-day cultures after primary activation (as described above) did not anergize T cells (data not shown). Thus, the mechanism of anergy induction seems to be independent of soluble factors and unrelated to generation of AAMU.
Anti-HLA-DR induces early phosphorylation of ERK in monocytes compared with late activation after anti-CD45 treatment
The exact mode of action of anti-HLA-DR and anti-CD45 on human monocytes is not fully understood. Both antibodies inhibit proliferation in primary cultures (as shown in Fig. 1A ), but only anti-HLA-DR transfers tolerance in vitro. To identify differences between these two agents on the molecular level, overall tyrosine phosphorylation has been studied with Fig. 2 . HLA-DR triggering on monocytes is sufficient to induce T cell anergy, but has no effect on activated T cells; it further suppresses monokine secretion and induces early ERK signaling in monocytes. (A) Monocytes or T cells were isolated as described in Methods and mock or anti-HLA-DR pre-treated. After extensive washing, each group was mixed with non-pre-treated T cells or monocytes, respectively, and activated during primary culture with OKT-3 for 5-7 days. After extensive washing 1 3 10 5 cells per well were re-stimulated with reagents as indicated (p.b. = plate bound). Proliferation was quantified as specified in Methods. Numbers are mean values 6 SEMs of two independent experiments. Statistical significance was calculated for optimally re-stimulated cells with IL-2 or p.b. OKT-3 + anti-CD28. P values for IL-2 re-stimulated cells are as follows: 'mock pre-treated' versus 'monocytes pre-treated', P = 0.0122 (*) and mock pre-treated versus 'T cells pre-treated', P = 0.2779 (not significant, ns). P values for p.b. OKT-3 + anti-CD28 re-stimulated cells: mock pre-treated versus monocytes pre-treated, P = 0.0266 (*) and mock pre-treated versus T cells pre-treated, P = 0.0629 (ns). (B) PBMCs were activated for 5-7 days during primary culture with OKT-3 alone. Cells were thoroughly washed, and 1 3 10 5 cells per well were re-stimulated with the reagents as indicated (p.b. = plate bound). 9.3F10 mAb was added during re-stimulation period (black bars). Proliferation was quantified as specified in Methods. Numbers indicate mean values 6 SEMs of three independent experiments. (C) PBMCs were activated for 5-7 days during primary culture with OKT-3 alone, OKT-3 plus 9.3F10 mAb or OKT-3 plus GAP8.3 mAb. Supernatants after primary culture were assessed for monokine secretion as described in Methods. Numbers indicate mean values 6 SEMs of six independent experiments. P values for TNFa secretion are as follows: OKT-3 pre-treated versus OKT-3/9.3F10 pre-treated, P = 0.0004 (***) and OKT-3 pre-treated versus OKT-3/GAP8.3 pre-treated, P = 0.0013 (**). P values for IL-1b secretion: OKT-3 pretreated versus OKT-3/9.3F10 pre-treated, P = 0.0288 (*) and OKT-3 pre-treated versus OKT-3/GAP8.3 pre-treated, P = 0.0310 (*). P values for IL-6 secretion: OKT-3 pre-treated versus OKT-3/9.3F10 pre-treated, P = 0.00481 (*) and OKT-3 pre-treated versus OKT-3/GAP8.3 pre-treated, P = 0.0217 (*). (D) Purified human monocytes were stimulated as indicated and the corresponding cellular lysates were analyzed by western blotting for the presence of phosphorylated ERK1/2. Identical blots were analyzed for the overall expression of ERK1/2 indicating equal expression and loading. Shown is one representative result out of three independent experiments. western blotting of lysates from purified human monocytes. However, no significant differences could be appreciated (data not shown). Next, ERK1/2 activation was examined as this kinase is known to be phosphorylated upon triggering HLA-DR molecules in monocytes (36) . Interestingly, phosphorylation kinetics differed between anti-HLA-DR-and anti-CD45-treated monocytes (Fig. 2D) . While anti-CD45 induced maximal phosphorylation of ERK after 30-60 min, anti-HLA-DR already strongly phosphorylated ERK after 5 min. As opposed to anti-CD45, ERK phosphorylation vanished by 60 min (Fig. 2D) . These findings could potentially explain why only anti-HLA-DR transfers tolerance in vitro, but not anti-CD45, although both inhibit proliferation during primary cultures. To further test this hypothesis, ERK activation was inhibited with a pharmacologic agent. This experiment should test whether secondary anergy induction via monocytes could be prevented when ERK phosphorylation was prevented. However, ERK inhibition (with inhibitor PD 98059) did not affect the capacity of anti-HLA-DR-treated monocytes to induce T cell anergy (data not shown) indicating that other signaling pathways are likely involved in generating a suppressive state in monocytes.
Partial reversal of anergy induction by IL-2, but not anti-CD28, during primary culture
In addition to characterizing which signals could reverse the effects of anti-HLA-DR-treated monocytes, we wanted to examine factors potentially affecting T cell anergy induction as well. Since the anergic cells were also refractory to re-stimulation with IL-2 (Fig. 1B) , we wondered whether IL-2 could affect anergy induction during the primary phase. Both IL-2 or costimulation via anti-CD28 have been shown to prevent anergy induction under certain conditions (62) (63) (64) . Adding physiological concentrations of IL-2 (10 U ml
À1
) during the primary incubation period could, however, only partially reverse the hyporesponsive state (Fig. 3) , whereas anti-CD28 did not influence the subsequent anergic state at all (data not shown).
Phenotypic and functional characterization of the anergic T cells
Since different states of anergy exist, we next wanted to further characterize the anergized cells. They were analyzed by flow cytometry for expression of various molecules after withdrawal from primary culture. CD3f chain was strongly reduced in the total cell population (Fig. 4A) as well as per single cell (32.2 6 0.4% reduction in mean fluorescence activity, data not shown). CD25, CD28 and intracellularly CTLA-4-expressing cells were also markedly diminished (Fig. 4B-D) . Activation-induced up-regulation of Fas and down-regulation of CD45RA were prevented as well (data not shown), whereas intracellular levels of anti-apoptotic molecule Bcl-2 remained unchanged (Fig. 4E) . Interestingly, except for CD3f chain, anti-CD45-pre-treated cells showed similar phenotypic changes-albeit not as pronounced-as the anergic cells (data not shown), despite their normal proliferative behavior upon re-stimulation (see Fig. 1B ). Importantly, although CD4:CD8 ratios were affected by anergy induction, total T cell numbers did not change (see Supplementary Figure 2 , available at International Immunology Online) indicating that CD3f-chain down-regulation is not due to decreased T cell numbers.
In order to detect functional changes reflected by the secretion pattern of the differently activated cells, various cytokines were measured in supernatants after secondary culture. T cells were stimulated to produce IL-2, IL-4, IL-10 or IFNc in response to plate-bound anti-CD3 alone or in combination with IL-2 or anti-CD28 (Fig. 5) . IL-2 (Fig. 5A) , IL-10 ( Fig. 5B) and IFNc (Fig. 5C ) secretions were reduced after 2 days of re-stimulation. This was specific for anti-HLA-DR-pre-treated cells with regards to IL-10 and IFNc. Surprisingly, anti-CD45-pre-treated cells demonstrated also impaired IL-2 secretion (Fig. 5A) , despite their intact proliferative capacity (see Fig. 1B ). IL-4 secretion was not detected after re-stimulation in any of the supernatants of all three groups (data not shown). Of note, IL-10 was not statistically significantly reduced (Fig. 5B) indicating that there was a relative increase of this immunosuppressive cytokine compared with the other cytokines measured, further supporting the tolerizing effect.
Molecular characterization of the anergized T cells
Molecular changes that are stable in anergized cells could potentially explain the persistent state of hyporesponsiveness. We therefore used high-throughput immunoblot analysis for selected proteins in order to better characterize the biochemical state in these cells. As expected, protein amounts from activated lymphoblasts were considerably higher than from anergized (anti-HLA-DR co-treated) or control cells (anti-CD45 co-treated). Consequently, we only used equivalent amounts of lysates from each experiment, pooled them and tested with a customized PowerBlot Miniarray for differences in anergy-relevant proteins (see Methods for details). Despite the robust differences in proliferation, only few changes were picked up on the protein level and two of them were followed up in order to better characterize the anergized cells.
Interestingly, caspase-3, an enzyme well known for executing cell death, was recently found to be up-regulated in murine T cell anergy (10) . However, it has also been demonstrated by several groups that caspase-3 is involved in proliferation (13) (14) (15) (16) . In line with this, we did not find increased caspase-3 on the protein level in our model of human T cell anergy. In fact, western blots against caspase-3 revealed no significant changes in uncleaved caspase-3, but strongly decreased levels of the cleaved form of caspase-3 (Fig. 6A,  upper panel) . In addition, enzymatic activities of caspase-3 and caspase-8 measured by an enzyme assay were strongly reduced as well (Fig. 6B) . Importantly, however, the decreased activities and levels of cleaved caspase-3 were also seen in the control lysates ( Fig. 6A and B) confirming that caspases are involved in T cell proliferation (11-16), but they do not seem to oppose anergy induction. This notion has also been indirectly supported by the fact that caspase inhibition with a pharmacological inhibitor (zVAD-fmk) did not facilitate induction of T cell anergy (data not shown).
These similarities of anti-HLA-DR-and anti-CD45-treated cells also on the biochemical level prompted us to search further for potential differences between the persistently hyporesponsive and the anti-CD45-inhibited cells. As cellcycle progression is required for continued proliferation during re-stimulation, we also investigated levels of cyclindependent kinase (CDK) inhibitors p21 cip1 and p27 kip1 . Indeed, both CDK inhibitors were selectively up-regulated in the anergized T cells, but not anti-CD3 6 anti-CD45-treated controls (Fig. 6A, lower panel) , in line with previous studies linking these cell-cycle regulators to T cell anergy (6, (17) (18) (19) (20) (21) (22) (23) (24) . be created if anti-proliferative signals are delivered that do not kill the target T cells. However, not every stimulus fulfilling these criteria induces long-lasting T cell hyporesponsiveness (65) . Finding new ways of inducing T cell anergy via direct or indirect pathways (i.e. tolerogenic APCs) will therefore help to understand the differences between cells or signals only briefly blocking T cells and those transferring profound hyporesponsiveness that persists even after removal of the initial inhibitory stimulus.
In this study, we have investigated the secondary effects of HLA-DR-ligated APCs on T cell phenotype and function. We could demonstrate that anti-HLA-DR mAbs modulate monocytes to become tolerogenic and induce T cell anergy refractory to IL-2 re-stimulation. This refractory state might be in part due to down-regulation of CD25 as seen in other states of T cell hyporesponsiveness [e.g. in trauma patients which exhibit depressed monocyte and T cell function (66)]. Anergy induction was independent of soluble factors or generation of AAMU. Interestingly, inhibition of proliferation with anti-CD45 revealed many similarities with the anergic T cells including reduced cleavage and activity of caspases in accordance with recent publications demonstrating that caspase-3 and caspase-8 are involved in T cell proliferation (11) (12) (13) (14) (15) (16) . However, the anergic cells could be distinguished from the responsive cells by selective up-regulation of CDK inhibitors p27 kip1 and p21 cip1 , both of which have been linked to T cell anergy in several models (6, (17) (18) (19) (20) (21) (22) (23) (24) .
We suggest two not mutually exclusive scenarios regarding a possibly physiological role for monocyte MHC class IImediated induction of T cell anergy in vivo. Monomorphic determinants of HLA molecules on APCs are bound by CD4 molecules on the interacting T cells (67) . Thus, one could envision that self-MHC molecules not only deliver continuously homeostatic signals to T cells (34) but also receive tolerogenic signals from resting T cells via CD4 co-receptors. In addition, anti-HLA-DR antibodies are produced during autoimmunity putatively as a negative feedback mechanism (68) . It might therefore be useful to enhance this mechanism by administration of exogenous anti-HLA-DR mAbs. In fact, in one study from 1982 it has been attempted to treat rheumatoid arthritis patients with placental-eluted gamma globulin (69) that was selectively directed against HLA-DR molecules (70) . Interestingly, this treatment has lead to substantial improvement of clinical disease (69) . It is, however, unclear whether HLA-DR-mediated tolerance was mechanistically involved in the observed improvement.
Anti-HLA-DR targets several populations of APCs. Thus, dendritic cells could also be in part responsible for the observed inhibitory effects in our experimental system. However, one key finding was that pre-treated monocytes were sufficient to induce anergy as shown in Fig. 2A . While it would be interesting to study the effect of anti-HLA-DR also on dendritic cells, the near complete effect seen with monocytes shifted the focus of our studies on this cell type. In addition, other groups have found that anti-HLA-DR leads to apoptosis of DCs further supporting that monocytes/macrophages are the key mediators of tolerance in our system (40, 45) . Again, our experiments with isolated populations of monocytes and T cells underscore this notion ( Fig. 2A) . Numbers indicate mean values 6 SEMs of three independent experiments. Statistical significance was calculated for each cytokine when significant secretion was elicited. P values for IL-2 secretion (A) after p.b. OKT-3 + anti-CD28 re-stimulation: OKT-3 pre-treated versus OKT-3/ 9.3F10 pre-treated, P = 0.0113 (*) and OKT-3 pre-treated versus OKT-3/GAP8.3 pre-treated, P = 0.0067 (**). P values for IL-10 secretion (B) after p.b. OKT-3 + IL-2 re-stimulation: OKT-3 pre-treated versus OKT-3/9.3F10 pre-treated, P = 0.2845 (not significant, ns) and OKT-3 pre-treated versus OKT-3/GAP8.3 pre-treated, P = 0.3837 (ns). P values for IFNc secretion (C) after p.b. OKT-3 + IL-2 secretion: OKT-3 pre-treated versus OKT-3/9.3F10 pre-treated, P = 0.002 (*) and OKT-3 pre-treated versus OKT-3/GAP8.3 pre-treated, P = 0.3188 (ns).
Interestingly, resting macrophages have recently been shown to induce allogeneic T cell anergy (32) . In addition, anergy-inducing MU have previously been described as a distinct phenotype after so-called alternative activation (AAMU) [reviewed in (27, 28, 60) ]. Our data suggest that at least MHC class II ligation can induce tolerogenic MU different from AAMU based on phenotypic analysis. As discussed above, soluble factors do not seem to be involved; instead, preliminary results after further characterization of the tolerized monocytes point toward increased numbers of cells expressing surface transforming growth factor b (TGFb) (with unchanged mean fluorescence). However, this needs to be investigated in more detail in the future including TGFb-blocking experiments to confirm the functional relevance of this subtle finding. Interestingly, anti-HLA-DR induced early phosphorylation of ERK compared with anti-CD45, although both agents inhibited proliferation during primary cultures. It was speculated that early ERK activation might be responsible for the suppressive effect of monocytes on T cells which become anergized. However, ERK inhibition did not alter the tolerogenic potential of anti-HLA-DR-treated monocytes in vitro (data not shown). Further studies are needed to identify the crucial signaling pathways in these monocytes and to distinguish between the heterogenous groups of tolerizing subtypes of macrophages (27, 28, 30, 60) .
It is noteworthy that anti-CD45 antibody GAP8.3 induced several similar changes in both the monocyte and T cell populations as anti-HLA-DR but failed to confer T cell hyporesponsiveness, the primary outcome studied in this model (see Figs 5A, 6A and B) . Both antigens are widely expressed and glycosylated (although CD45 more extensively). Both inhibit significantly primary activation of monocytes and T cells as described above (see Figs 1A and 2C ). These findings further strengthen anti-CD45 as a rigorous control agent in this experimental system. Plain isotype controls without functional consequences are often used as controls for studying antibody-mediated phenomena (56) . However, when examining T cell hyporesponsiveness, it is useful to create equivalent inhibition during primary culture with a control agent that does not induce hyporesponsiveness during secondary culture (i.e. during the re-stimulation phase testing hyporesponsiveness). This way, subtle differences between T cell quiescence versus anergy can be appreciated. Our data suggest that there are indeed many similarities between a quiescent state (with the potential to be re-stimulated) and anergy (indicated by hypoproliferation during re-stimulation). This approach might be useful to potentially identify key pathways that would otherwise not be apparent with conventional isotype controls.
Despite the attempts to unify models of T cell anergy, different forms seem to exist depending on depth, mechanism of induction, reversibility and acquisition of suppressor function (4, 19, 71) . The anergic cells characterized here are refractory to IL-2 as described in some models (19, 56) and preliminary experiments suggest that they do not acquire suppressor function as seen under certain conditions as well (56, 71) . This might be due to profound inhibition of multiple cytokines (56) . In vivo, deletion together with anergy is sufficient for early tolerance induction after allogeneic bone cip1 and p27 kip1 and measurement of caspase-3 and -8 activities. (A) PBMCs were activated for 5-7 days during primary culture with OKT-3 alone, OKT-3 plus 9.3F10 mAb or OKT-3 plus GAP8.3 mAb. After primary culture, cells were lysed and equal amounts of protein examined for expression levels of intact and cleaved (activated) caspase-3 (A, upper panel) as well as p21 cip1 and p27 kip1 (A, lower panel). The lower of the two bands on the p27 kip1 blot represents p27 kip1 as confirmed by western blotting and comparison with lysates from other cell types (e.g. HeLa cells) that do not express the protein responsible for the non-specific band above p27 kip1 (data not shown). One of three to five blots with similar results is shown for each of the examined proteins. (B) Caspase-3 and caspase-8 activities were also measured at the end of primary culture as described in Methods. Caspase activities are shown from one of three experiments with comparable results. marrow transplantation without the need for generating regulatory cells (72) , indicating that anergy and suppressor function do not necessarily need to be connected.
Recent advances regarding the molecular mechanisms underlying murine T cell anergy point toward a central role for pathways involved in ubiquitin-mediated protein degradation [reviewed in (7) ]. While most of the findings have only been studied in murine models of T cells anergy, a dominant theme in human and murine T cell anergy is that cell-cycle inhibitors are up-regulated (6, (17) (18) (19) (20) (21) (22) (23) (24) . Indeed, the CDK inhibitors p27 kip1 and p21 cip1 were also selectively up-regulated in the anergized T cells of our experimental system. Further investigations are needed to fully delineate the subtle differences between anergized and transiently inhibited T cells. We believe that this model of T cell tolerance should provide a useful tool to dissect the molecular alterations in more detail that distinguish between these states.
In summary, we have shown that HLA-DR ligation transforms human monocytes into tolerogenic cells, enabling them to induce T cell anergy independent of soluble factors. The anergic state was characterized by defective cytokine secretion and proliferation refractory to exogenous IL-2. The silenced T cells displayed selective up-regulation of cell-cycle inhibitors p27 kip1 and p21 cip1 in line with a functional role of these molecules in human T cell anergy (6, (17) (18) (19) (20) (21) (22) (23) . HLA-DRdirected therapeutic strategies might be promising for the treatment of autoimmune diseases, transplant rejection, allergies or comparable immune-mediated disease states that require silencing of both APCs and T cells to achieve sustained immune tolerance. Finally, our study possibly contributes to a better understanding of the role of naturally produced anti-MHC class II antibodies during autoimmunity (68) . Supplementary Figures 1-3 
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